Europium chloride, anhydrous 99.9% → Thyroxine

HRID 257615

反応式

HRID 257615 の反応式
[Cl-].[Eu+3].[Cl-].[Cl-].[Na+].[NH2:6][C@H:7]([C:27]([O-:29])=[O:28])[CH2:8][C:9]1[CH:16]=[C:14]([I:15])[C:13]([O:17][C:18]2[CH:25]=[C:23]([I:24])[C:22]([OH:26])=[C:20]([I:21])[CH:19]=2)=[C:11]([I:12])[CH:10]=1>CN(C)C=O.C(O)C>[NH2:6][C@H:7]([C:27]([OH:29])=[O:28])[CH2:8][C:9]1[CH:10]=[C:11]([I:12])[C:13]([O:17][C:18]2[CH:19]=[C:20]([I:21])[C:22]([OH:26])=[C:23]([I:24])[CH:25]=2)=[C:14]([I:15])[CH:16]=1

参加物

5

反応物 2

HCID 9859933Europium chloride, anhydrous 99.9%HCID 23666112Levothyroxine Sodium2 回

生成物 1

HCID 5819Thyroxine

試薬・触媒・溶媒 2

HCID 702Ethanol溶媒2 回HCID 6228Dimethylformamide溶媒

実験手順

Fluorescent compound (v) synthesized in Example 4 was dissolved in dimethylformamide at a concentration of 5.0×10-5M, and thyroxine sodium salt was dissolved in ethanol at a concentration of 5.0×10-5M. The fluorescent compound (v) solution (100 μl) and the thyroxine sodium salt solution (100 μl) of ethanol were mixed and incubated for 30 minutes at room temperature with stirring. The resulting solution was subjected to a HPLC purification (column: AP-313, YMC Co., solvent: methanol: water=3:7(v:v) including 0.02% acetic acid) and the fluorescent compound (v)-labelled thyroxine was purified. The fluorescent compound (v)-labelled thyroxine was identified by measuring the thyroxine activity using an enzyme immunoassay (Boehringer Mannheim GmbH), and by measuring fluorescence intensity of the solution prepared by mixing equal volume of europium chloride (1×10-5M) and the fraction.

後処理

  1. customThe resulting solution was subjected to a HPLC purification (column: AP-313, YMC Co., solvent: methanol: water=3:7(v:v)
  2. customwas purified
  3. customprepared

出典と根拠

ORDレコード
ord-47de7a514e3547679a0e2c8e966c64ef
出典データセット
uspto-grants-1993_11
特許番号
US05262526

関連ノート

読み込み中…